ArticleJournal of natural medicines2026
Two novel compounds (lovastatin analog Y and lovastatin analog Z) isolated from health foods containing beni-koji (red yeast rice) with adverse events report.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ingestion of a contaminated health food product containing beni-koji (red yeast rice), one of the so-called "Foods with Functional Claims (FFC),'' was recently reported to have adverse health effects, such as kidney damage. We previously revealed the presence of unexpected components, namely lovastatin analog Y and lovastatin analog Z, in contaminated FFC samples, which, incidentally, also contained puberulic acid. However, the structures and stereochemistries of these novel compounds remain unknown. In this study, we addressed this by conducting a comprehensive instrumental analysis of lovastatin analogs Y and Z isolated from the FFC samples. The two-dimensional structures of the isolated compounds were determined by ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS) and NMR spectroscopy. Their absolute configurations were established by comparison with those of chemically synthesized lovastatin analogs Y and Z. X-ray structural analysis using the crystalline sponge method confirmed that the synthesized lovastatin analogs Y and Z have the same absolute configuration as lovastatin acid. UHPLC-HRMS and NMR analyses further showed that the absolute configurations of lovastatin analogs Y and Z isolated from the FFC samples are identical to those of the synthesized compounds. Considering that lovastatin analogs Y and Z are produced through the co-incubation of Monascus pilosus and Penicillium adametzioides, these findings are expected to contribute to biosynthetic research related to these fungal species.
Indexed as
Identifiers
42477306What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.